Skip to main content
SpringerLink
Log in

Tofacitinib increases risk of MACE and cancer versus TNF inhibitors

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Ytterberg SR, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. New England Journal of Medicine 386: 316-326, No. 4, 27 Jan 2022. Available from: URL: http://doi.org/10.1056/NEJMoa2109927

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tofacitinib increases risk of MACE and cancer versus TNF inhibitors. Reactions Weekly 1893, 12 (2022). https://doi.org/10.1007/s40278-022-09795-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-09795-6

Search

Navigation